Featured Research

from universities, journals, and other organizations

'Junk DNA' drives cancer growth, Hodgkin's lymphoma study finds

Date:
May 3, 2010
Source:
University of Leeds
Summary:
Researchers have discovered a new driving force behind cancer growth. New studies have identified how 'junk' DNA promotes the growth of cancer cells in patients with Hodgkin's lymphoma.

Researchers have discovered a new driving force behind cancer growth. New studies have identified how 'junk' DNA promotes the growth of cancer cells in patients with Hodgkin's lymphoma.
Credit: iStockphoto/Alan John Lander Phillips

Researchers from the University of Leeds, UK, the Charité University Medical School and the Max Delbrück Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.

Related Articles


Their studies have identified how 'junk' DNA promotes the growth of cancer cells in patients with Hodgkin's lymphoma. Professor Constanze Bonifer (University of Leeds) and Dr Stephan Mathas (Charité, MDC) who co-led the study suspect that these pieces of 'junk' DNA, called 'long terminal repeats', can play a role in other forms of cancer as well. The work is published in Nature Medicine.

The researchers uncovered the process by which this 'junk DNA' is made active, promoting cancer growth.

"We have shown this is the case in Hodgkin's lymphoma, but the exact same mechanism could be involved in the development of other forms of blood cancer," said Prof. Bonifer. "This would have implications for diagnosis, prognosis, and therapy of these diseases."

'Long terminal repeats' (LTRs) are a form of 'junk DNA' -- genetic material that has accumulated in the human genome over millions of years. Although LTRs originate from viruses and are potentially harmful, they are usually made inactive when embryos are developing in the womb.

If this process of inactivation doesn't work, then the LTRs could activate cancer genes, a possibility that was suggested in previous animal studies. This latest research has now demonstrated for the first time that these 'rogue' active LTRs can drive the growth of cancer in humans.

The work focused on cancerous cells of Hodgkin's lymphoma (the Hodgkin-/Reed Sternberg cells) that originate from white blood cells (antibody-producing B cells). Unusually, this type of lymphoma cell does not contain a so-called 'growth factor receptor' that normally controls the growth of other B-cells.

They found that the lymphoma cells' growth was dependent on a receptor that normally regulates the growth of other immune cells, but it is not usually found in B-cells. However in this case, the Hodgkin-/Reed Sternberg cells 'hijacked' this receptor for their own purposes by activating some of the 'junk DNA'. In fact the lymphoma cells activated hundreds, if not thousands, of LTRs all over the genome, not just one.

Hodgkin-/Reed Sternberg cells may not be the only cells that use this method to subvert normal controls of cell growth. The researchers found evidence of the same LTRs activating the same growth receptor in anaplastic large cell lymphoma, another blood cancer.

The consequences of such widespread LTR activation are currently still unclear, according to the study's authors. Such processes could potentially activate other genes involved in tumour development. It could also affect the stability of chromosomes of lymphoma cells, a factor that may explain why Hodgkin-/Reed Sternberg cells gain many chromosomal abnormalities over time and become more and more malignant.

Background

1. There are about 1,300 new cases of Hodgkin's lymphoma each year in the UK, including 150 in children.

2. LTR fragments were originally formed by infection with retroviruses, a type of virus that can integrate their own genetic material into a host gene. The human genome contains thousands of these LTR fragments.

3. The receptor that was observed to control cell growth in Hodgkin-/Reed Sternberg cells is known as CSF1R (the colony stimulating factor 1 receptor).


Story Source:

The above story is based on materials provided by University of Leeds. Note: Materials may be edited for content and length.


Journal Reference:

  1. Björn Lamprecht, Korden Walter, Stephan Kreher, Raman Kumar, Michael Hummel, Dido Lenze, Karl Köchert, Mohamed Amine Bouhlel, Julia Richter, Eric Soler, Ralph Stadhouders, Korinna Jöhrens, Kathrin D Wurster, David F Callen, Michael F Harte, Maciej Giefing, Rachael Barlow, Harald Stein, Ioannis Anagnostopoulos, Martin Janz, Peter N Cockerill, Reiner Siebert, Bernd Dörken, Constanze Bonifer & Stephan Mathas. De-repression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nature Medicine, May 2, 2010 DOI: 10.1038/nm.2129

Cite This Page:

University of Leeds. "'Junk DNA' drives cancer growth, Hodgkin's lymphoma study finds." ScienceDaily. ScienceDaily, 3 May 2010. <www.sciencedaily.com/releases/2010/05/100502173845.htm>.
University of Leeds. (2010, May 3). 'Junk DNA' drives cancer growth, Hodgkin's lymphoma study finds. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2010/05/100502173845.htm
University of Leeds. "'Junk DNA' drives cancer growth, Hodgkin's lymphoma study finds." ScienceDaily. www.sciencedaily.com/releases/2010/05/100502173845.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins